PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS

Regional Analysis

Global Plasma Protease C1-inhibitor Treatment Market - Regional Analysis

On the basis of region, the global plasma protease C1-inhibitor treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, owing to increasing approvals of novel therapies by the regulatory agencies such as the U.S. Food and Drug Administration. For instance, in 2014, the U.S. FDA approved Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of the Middle East
• Africa: South Africa, North Africa, and Central Africa